© 2024
© 2024
Using a comprehensive suite of analytical techniques we ensure precise characterization and rigorous quality control of your bioconjugate. These methods include advanced chromatography, native intact mass (MS), denatured intact mass, peptide mapping and biophysical characterization to provide detailed insights into the molecular composition, conjugation sites, and structural integrity of your product. Our comprehensive approach delivers confidence in the quality and consistency of your bioconjugates at every stage.
Test your discovery-stage ADC further with functional testing, such as cell-based assays and receptor binding. Our experts develop bioassays for assessment of potency, efficacy and safety, giving you the benefit of our experience across a diverse range of modalities. To help understand your molecule in detail our assays include luminescence, fluorescence, absorbance plate-based assays, Flow cytometry, live cell imaging and Cytokine analysis.
Determination of drug loading (DAR), Analysis of conjugation site, Analysis of ADC homogeneity, Chromatographic and spectroscopic purity, Quantification of residual unconjugated drug and Aggregation profile
We design and deliver tailored solutions using our conjugation chemistries, assembling a variety antibody-drug conjugates (ADC), antibody fragment-drug conjugates (ScFvDC), antibody-oligonucleotide conjugates (AOC, Bispecific Antibodies (bsAbs) and other protein- and peptide-drug conjugates.
Leverage our experience in the synthesis of payloads, linkers, and payload-linker chemical to enable the rapid generation of structure activity relationships (SAR) of various linker combinations with your new payloads. Accelerating and de-risking the development and manufacture of your next-generation therapies, Our integrated approach supports the lifecycle of ADC discovery and development.
We design and deliver tailored solutions using our conjugation
chemistries, assembling a variety antibody-drug conjugates (ADC),
antibody fragment-drug conjugates (ScFvDC), antibody-oligonucleotide
conjugates (AOC, Bispecific Antibodies (bsAbs) and other protein- and
peptide-drug conjugates
Linker payload design & synthesis
We design and deliver tailored solutions using our antibody-oligonucleotide
conjugates (AOC, Bispecific Antibodies (bsAbs) and other protein- and
peptide-drug conjugates.
We design and deliver tailored solutions using our conjugation
chemistries, assembling a variety antibody-drug conjugates (ADC),
antibody fragment-drug conjugates (ScFvDC), antibody-oligonucleotide
conjugates (AOC, Bispecific Antibodies (bsAbs) and other protein- and
peptide-drug conjugates
Leverage our experience in the synthesis of payloads. . .
Genie Biotech will perform a structural assessment using our suite of chromatographic, Mass Spectrometric and Biophyscial instrumentation to confirm the viability of your new bioconjugate before returning it to you.
Genie Biotech will either receive your candidate(s) of interest or synthesize it and begin the work of assembling your conjugate of choice. In combination with our high throughput approach, and unique sitespecific chemistries we can quickly identify the most promising candidates for stability and scalability.
As an extension of your team, we would develop a strategy tailored to your specific product, proposing the experimental matrix, deliverables, expected timelines and even exploring the IP landscape.
Leave the assembling to us
Whether you are looking to make a custom purification column or a specific ADC, leverage our dedicated team to assemble and test your desired product.
Mammalian and Bacterial Expression systems
Genie Biotech can offer recombinant protein production services from our in-house BSL-2 facility.
Structural Characterisation
Using our suite of Chromatographic, Mass Spectrometric and Biophysical instruments we have the capability to monitor, asses and qualify your conjugates
Site-specific chemistries,
payloads & ready-made
conjugates
Explore our bioconjugation toolbox and Purchase off-the-shelf products developed for your early stage research.